Welcome to our dedicated page for Varex Imaging news (Ticker: VREX), a resource for investors and traders seeking the latest updates and insights on Varex Imaging stock.
Varex Imaging Corporation (VREX) delivers critical x-ray components for medical diagnostics and industrial inspection systems worldwide. This page provides investors and industry professionals with a comprehensive resource for tracking the company's latest press releases, financial announcements, and strategic developments.
Find timely updates on quarterly earnings, new product launches, and partnerships that shape Varex's leadership in imaging technology. Our curated collection includes regulatory filings, manufacturing innovations, and market expansion updates across both medical and industrial segments.
Bookmark this page to monitor how Varex's advancements in digital detectors, x-ray tubes, and quality engineering impact global healthcare and industrial inspection markets. Check regularly for objective reporting on developments affecting the medical imaging supply chain and non-destructive testing solutions.
Varex Imaging Corporation (Nasdaq: VREX) will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 1:10 pm ET. The company’s CFO, Sam Maheshwari, will discuss Varex’s business and future prospects. The presentation will be webcast and accessible on the company’s website, with replays available for 90 days. Varex specializes in designing and manufacturing X-ray imaging components, playing a crucial role in medical and industrial applications, with over 2,000 employees worldwide.
Varex Imaging Corporation (Nasdaq: VREX) reported its 1QFY21 financial results, showing revenues of $177 million, a 4% increase sequentially from 4QFY20. The company achieved a GAAP gross margin of 32% and a non-GAAP gross margin of 34%, reflecting a 580 basis points improvement due to cost reductions and a favorable product mix. GAAP net earnings were $(0.16) per diluted share, while non-GAAP earnings were $0.08. The outlook for 2QFY21 estimates revenues between $180 million and $200 million and non-GAAP earnings per diluted share between $0.05 and $0.25.
Varex Imaging Corporation (Nasdaq: VREX) will release its unaudited financial results for Q1 FY2021 on February 4, 2021, after market close. A conference call is scheduled for 3:00 PM MT the same day, available via webcast on the company’s investor site and through designated phone numbers. The replay will be accessible until February 18, 2021. Varex Imaging specializes in X-ray imaging components, with over 70 years of innovation in medical, industrial, and security applications, employing about 2,000 staff globally.
Varex Imaging Corporation (Nasdaq: VREX) will present at two virtual investor conferences in January 2021. The first is at the CJS Securities 21st Annual New Ideas for the New Year Conference on January 13, 2021, at 1:35 pm ET. The second presentation is at the Sidoti Winter 2021 Investor Conference on January 14, 2021, at 11:30 am ET. CFO Sam Maheshwari will discuss Varex's business and future prospects. Webcast links are available for both events, and replays will be accessible for 90 days on the company's website.
Varex Imaging Corporation (Nasdaq: VREX) announced its 2021 Annual Meeting of Stockholders will be held virtually on February 11, 2021, at 2:00 PM Mountain Time due to COVID-19 restrictions. Stockholders of record as of December 18, 2020, are eligible to vote on meeting matters. Varex will provide necessary information on attending the virtual meeting and encourages stockholders to vote and submit proxies in advance. Varex is a leader in X-ray imaging components, supplying products for medical, industrial, and security applications, employing approximately 2,000 people globally.
Varex Imaging Corporation (Nasdaq: VREX) will present its advanced X-ray technologies at the RSNA 2020, taking place virtually from November 29 to December 5, 2020. Key highlights include intro of nanotube-based X-ray tubes and Liquid Metal Bearing (LMB) X-ray tubes, enhancing efficiency and lifespan. Additionally, Varex will showcase photon counting digital detectors and the Z Platform digital detector, promising improved imaging capabilities. A virtual booth featuring 3D models and product videos will also be launched to engage participants.
Varex Imaging Corporation (Nasdaq: VREX) reported its unaudited financial results for Q4 and fiscal year 2020. Q4 revenues reached $170 million, with a GAAP gross margin of 27% and a net loss of $0.66 per diluted share. For the full year, revenues totaled $738 million, with a GAAP gross margin of 26% and a net loss of $1.47 per diluted share. Despite a decline in sales for some products, Varex noted improved margins due to cost reduction actions. The company expects Q1 FY2021 revenue guidance between $160 million and $180 million.
Varex Imaging Corporation (Nasdaq: VREX) will announce its unaudited financial results for Q4 and fiscal year 2020 on November 17, 2020, post-market close. A conference call will follow at 3:00 PM MT, accessible via the company’s website or by phone. Varex specializes in X-ray imaging components, offering products like X-ray tubes and digital detectors used in medical and security applications, with a workforce of about 2,000 employees worldwide.
Varex Imaging Corporation (Nasdaq: VREX) has completed a private offering of $300 million in 7.875% senior secured notes due 2027 at face value. In conjunction with this, Varex secured a $100 million asset-based revolving credit facility. The funds from the notes will be used to pay off the previous credit facility, alleviating concerns about the company's financial viability. The remaining proceeds will enhance cash reserves for general corporate purposes. This strategic move aims to strengthen Varex's financial position and support its ongoing operations.
Varex Imaging Corporation (Nasdaq: VREX) has priced a private offering of $300 million in senior secured notes due 2027, with a yield of 7.875%. The net proceeds will be used to repay existing credit facility obligations and for general corporate purposes. The offering is set to close on September 30, 2020, and is accompanied by a potential $100 million asset-based revolving credit facility, though its effectiveness is uncertain. The notes will be secured by various assets, and are being offered under regulations that limit their resale.
